The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, this time in relation to observations from the regulator's inspection at a ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by ...

The FDA had set an Aug. 19 target action date for the company's application, which was seeking a green light for Eylea HD for the treatment of macular edema following retinal vein occlusion and for ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

President Donald Trump has given leading pharma manufacturers a 60-day deadline to come up with a most favoured nation (MFN) ...

On July 14, 2025 Fresenius filed two IPR petitions challenging Regeneron’s patents related to aflibercept. Regeneron has not asserted that ...

Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilum ...